Jupiter Life Line Hospitals Limited IPO

Price
₹695 - ₹735
Lot
20
Subs.
64.8
Expected Listing Earning

Exp. Premium(GMP):
235.20(32.00%)
IPO Details

Open Date: 06-Sep-2023
Close Date: 08-Sep-2023
Allotment Date: 13-Sep-2023
Listing Date: 18-Sep-2023
Listing Price: ₹1112.45/-
Face Value: ₹10 Per Equity Share
Issue Price: ₹695-735 Per Equity Share
Issue Size: Total Issue Size 11,824,163 shares (aggregating up to ₹869.08 Cr) : Fresh Issue 7,374,163 shares (aggregating up to ₹542.00 Cr) : Offer for Sale 4,450,000 shares of ₹10 (aggregating up to ₹327.08 Cr)
Market Lot (Min Amount): Retail - ₹14,700 : S-HNI - ₹205,800 : B-HNI - ₹1,014,300
Subscription Details Updated at End of the Day

As on

QIB

Nll

Rll

Total

Shares Offered/Reserved2,443,7431,773,6254,138,4588,355,826
Day 1 - 06-09-23 
05:00 PM
0.01x1.49x1.17x0.90x
Day 2 - 07-09-23 
05:00 PM
1.09x6.88x3.23x3.38x
Day 3 - 08-09-23 
05:00 PM
181.89x36.00x8.00x64.80x
Total No. of Application:1,460,441 (Approx.)
Retail Subscription on the basis of Apps:7.06x
Valuations

Earning Per Share(EPS)13.95/-
P/E Ratio52.68
RoNW20.03%
Net Asset Value (NAV) - Post Issue:₹N/A/-
Company Financials (in Crore)

 Total AssetsTotal RevenueProfit After Tax
31 Mar,2023985.53902.9672.91
31 Mar,2022908.70737.1451.13
31 Mar,2021788.91490.27-2.30
Promoter(s)

Pre Issue Share Holding49.79%
Post Issue Share Holding40.91%
Company Promoter(s)
1. Dr. Ajay Thakker
2. Dr. Ankit Thakker
3. Wester Medical Solutions LLP
Issue Objective(s)

The company intends to utilize the net proceeds from the issue towards the funding of the following objects:

  1. Repayment/pre-payment, in full or part, of borrowings availed from banks by the company and Material Subsidiary; and
  2. General corporate purposes.
About Company

Incorporated in 2007, Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area (MMR) and western region of India.

Jupiter Life Line Hospitals has been operating as a corporate quaternary care healthcare service provider in the western regions of India and currently operates three hospitals under the "Jupiter" brand in Thane, Pune, and Indore, with a total operational bed capacity of 1194 beds, and 1,306 doctors including specialists, physicians, and surgeons, as of March 31, 2023. The company is currently developing a multi-specialty hospital in Dombivli, Maharashtra, which is designed to accommodate over 500 beds and has commenced construction in April 2023.

According to the CRISIL Report, the company's Thane and Indore hospitals are amongst the few hospitals in the western region of India to provide neuro-rehabilitation services through a dedicated robotic and computer-assisted neuro-rehabilitation center. Additionally, it operates one of the few multi-organ transplant centers in Thane. All the hospitals in Thane, Pune, and Indore have been certified by the National Accreditation Board for Hospitals & Healthcare Providers (NABH) and have been accredited in the field of medical testing by the National Accreditation Board for Testing and Calibration Laboratories (NABL).

The company's inpatient and outpatient revenue is diversified across hospitals with Thane, Pune, and Indore hospitals accounting for 54.18%, 34.03%, and 11.79%, respectively, of the revenue from operations in Fiscal 2023.

Disclaimer

No financial information whatsoever published anywhere, within this application, should be considered as an advise to buy or sell securities or invest in IPOs, or as guide to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. 

Also we are not a SEBi registered analyst comapny. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this application. Above information is based on information available as on date coupled with market perceptions.

If you are agree with app tems and condition to use the app. 

Thank you.